Yang Jie, Tan Chunlu, Liu Ya, Zheng Zhenjiang, Liu Xubao, Chen Yonghua
Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.
Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610065, China.
Biomedicines. 2024 Jul 24;12(8):1653. doi: 10.3390/biomedicines12081653.
New-onset diabetes (NOD) has been identified as a high-risk factor for the early detection of pancreatic ductal adenocarcinoma (PDAC). The role of tumor volume and remnant pancreas volume (RPV) in the progression from normal to NOD in PDAC patients is not fully illustrated yet.
In this cross-sectional study, glycemic metabolism traits of 95 PDAC patients before pancreatic surgery were described and compared with chronic pancreatitis and type 2 diabetes mellitus patients based on the oral glucose tolerance test. The remnant RPV and tumor volume, calculated by three-dimensional reconstruction of radiological images, were included in the ordinal logistic regression models.
The prevalence of NOD was high among PDAC patients (38.9%). However, normal glucose tolerance (NGT) or prediabetes mellitus status were present as more than half (24/44) of advanced tumor stage patients. Indexes reflecting beta-cell function but not insulin sensitivity gradually worsened from NGT to NOD patients (all < 0.05). The remnant pancreas volume (RPV) was identified as a potential protective factor for diabetes secondary to PDAC (odds ratio 0.95, 95% CI [0.92, 0.97], < 0.001).
Reduced RPV causing beta-cell dysfunction might be one of the mechanisms of NOD secondary to PDAC. Subjects with sufficient pancreas volume could not be detected earlier when regarding patients with NOD as the population at risk for PDAC.
新发糖尿病(NOD)已被确定为早期检测胰腺导管腺癌(PDAC)的高危因素。肿瘤体积和残余胰腺体积(RPV)在PDAC患者从正常状态进展为NOD过程中的作用尚未完全阐明。
在这项横断面研究中,描述了95例PDAC患者胰腺手术前的糖代谢特征,并基于口服葡萄糖耐量试验与慢性胰腺炎和2型糖尿病患者进行比较。通过放射影像三维重建计算得出的残余RPV和肿瘤体积被纳入有序逻辑回归模型。
PDAC患者中NOD的患病率较高(38.9%)。然而,超过一半(24/44)的晚期肿瘤分期患者存在正常糖耐量(NGT)或糖尿病前期状态。反映β细胞功能而非胰岛素敏感性的指标从NGT患者到NOD患者逐渐恶化(均P<0.05)。残余胰腺体积(RPV)被确定为PDAC继发糖尿病的潜在保护因素(比值比0.95,95%可信区间[0.92,0.97],P<0.001)。
RPV减少导致β细胞功能障碍可能是PDAC继发NOD的机制之一。将NOD患者视为PDAC高危人群时,无法更早发现胰腺体积充足的患者。